Radioactive Compounds That May Require Temporary Cessation of Breastfeeding: Recommendations of the International Commission on Radiologic Protection
Compound . | Examples . | Example of Procedures . | Recommended Time for Cessation of Breastfeeding . | Comments . |
---|---|---|---|---|
14C-labeled | Triolein, glycocholic acid, urea | Helicobacter pylori breath test | None | No approved US products |
99mTc-labeled | DMSA, DTPA, phosphonates (MDP), PYP, tetrofosmin | Multiple: imaging of kidney, bone, lung, heart, tumors | 0 to 4 h, as long as no free pertechnetate | Consider discarding at least 1 meal after procedure |
Microspheres, pertechnetate, WBC | 12–24 h | Range depends on dose | ||
Sulfur-colloids, RBC in vivo | 6 h | |||
I-labeled | 123I, 125I or 131I-iodo hippurate | Thyroid imaging | 12 h | Note: whole-body irradiation with 131I requires prolonged cessation |
Others | 11C- 11N or 11O-labeled | PET scans | None | Short physical half-life |
57Co-labeled vitamin B12 | Schilling test | 24 h | Pomeroy 2005119 | |
18F-FDG | PET scans | None, first feeding should be expressed breast milk to avoid direct contact120 | Use alternatives for 10 half-lives (10×109 min= 18 h)a | |
51Cr-EDTA | Renal imaging | None | ||
81mKr-gas | Pulmonary imaging | None | No approved US products | |
82Rb chloride | PET scan of myocardium | May resume 1 h after last infusion | Half-life 75 sa | |
111In-octreotide | SPECT, neuroendocrine tumors | None | ||
111In -WBC | 1 wk | Depends on dose | ||
133Xe | Cardiac, pulmonary, and cerebral imaging | None | Half-life 5 da |
Compound . | Examples . | Example of Procedures . | Recommended Time for Cessation of Breastfeeding . | Comments . |
---|---|---|---|---|
14C-labeled | Triolein, glycocholic acid, urea | Helicobacter pylori breath test | None | No approved US products |
99mTc-labeled | DMSA, DTPA, phosphonates (MDP), PYP, tetrofosmin | Multiple: imaging of kidney, bone, lung, heart, tumors | 0 to 4 h, as long as no free pertechnetate | Consider discarding at least 1 meal after procedure |
Microspheres, pertechnetate, WBC | 12–24 h | Range depends on dose | ||
Sulfur-colloids, RBC in vivo | 6 h | |||
I-labeled | 123I, 125I or 131I-iodo hippurate | Thyroid imaging | 12 h | Note: whole-body irradiation with 131I requires prolonged cessation |
Others | 11C- 11N or 11O-labeled | PET scans | None | Short physical half-life |
57Co-labeled vitamin B12 | Schilling test | 24 h | Pomeroy 2005119 | |
18F-FDG | PET scans | None, first feeding should be expressed breast milk to avoid direct contact120 | Use alternatives for 10 half-lives (10×109 min= 18 h)a | |
51Cr-EDTA | Renal imaging | None | ||
81mKr-gas | Pulmonary imaging | None | No approved US products | |
82Rb chloride | PET scan of myocardium | May resume 1 h after last infusion | Half-life 75 sa | |
111In-octreotide | SPECT, neuroendocrine tumors | None | ||
111In -WBC | 1 wk | Depends on dose | ||
133Xe | Cardiac, pulmonary, and cerebral imaging | None | Half-life 5 da |
DMSA, dimercaptosuccinic acid; DTPA, diethylenetriaminepentaacetate; EDTA, ethylenediaminetetraacetic acid; FDG, fludeoxyglucose; PET, positron emission tomography; PYP, pyrophosphate; RBC, red blood cell; SPECT, single-photon emission computed tomography; WBC, white blood cell.
FDA-approved drug labeling.